Home >> Research Area >>Natural Products>>Alkaloids>> Dehydroglaucine

Dehydroglaucine

CAS# 22212-26-6

Dehydroglaucine

2D Structure

Catalog No. BCN2548----Order now to get a substantial discount!

Product Name & Size Price Stock
Dehydroglaucine: 5mg Please Inquire In Stock
Dehydroglaucine: 10mg Please Inquire In Stock
Dehydroglaucine: 20mg Please Inquire Please Inquire
Dehydroglaucine: 50mg Please Inquire Please Inquire
Dehydroglaucine: 100mg Please Inquire Please Inquire
Dehydroglaucine: 200mg Please Inquire Please Inquire
Dehydroglaucine: 500mg Please Inquire Please Inquire
Dehydroglaucine: 1000mg Please Inquire Please Inquire

Quality Control of Dehydroglaucine

3D structure

Package In Stock

Dehydroglaucine

Number of papers citing our products

Chemical Properties of Dehydroglaucine

Cas No. 22212-26-6 SDF Download SDF
PubChem ID 398788 Appearance Cryst.
Formula C21H23NO4 M.Wt 353.41
Type of Compound Alkaloids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
SMILES CN1CCC2=CC(=C(C3=C4C=C(C(=CC4=CC1=C23)OC)OC)OC)OC
Standard InChIKey RZUHGAKUNBFQJS-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H23NO4/c1-22-7-6-12-9-18(25-4)21(26-5)20-14-11-17(24-3)16(23-2)10-13(14)8-15(22)19(12)20/h8-11H,6-7H2,1-5H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Dehydroglaucine

The tubers of Corydalis yanhusuo

Biological Activity of Dehydroglaucine

DescriptionDehydroglaucine is an acetylcholinesterase inhibitor, it shows antimicrobial activity against Staphylococcus aureus, Mycobacterium smegmatis, Candida albicans, and Aspergillus niger.
TargetsAntifection
In vitro

Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L.[Reference: WebLink]

Journal of Pharmaceutical Sciences, 1975, 64(5):789-792.

Alcoholic extracts of the heartwood of Liriodendron tulipifera have demonstrated antimicrobial activity against Staphylococcus aureus, Mycobacterium smegmatis, Candida albicans, and Aspergillus niger. The antimicrobial activity was associated only with the alkaloidal fraction.
METHODS AND RESULTS:
Separation of the active alkaloidal fraction by chromatography led to the isolation and identification of Dehydroglaucine and liriodenine as the active components.
CONCLUSIONS:
Several other alkaloidal derivatives were prepared and tested. In addition to the active alkaloids, michelabine was also identified in the tertiary nonphenolic base fraction along with the lignan, lirioresinol-B-dimethyl ether, and two N-acetylnoraporphine alkaloids from the nonbasic fraction.

Protocol of Dehydroglaucine

Structure Identification
RSC Adv. 2016, 6(100):98476-98486.

Zeolite based solid-phase extraction coupled with UPLC-Q-TOF-MS for rapid analysis of acetylcholinesterase binders from crude extract of Corydalis yanhusuo.[Reference: WebLink]

A very convenient, sensitive and precise solid-phase extraction approach was established for extract and analysis of acetylcholinesterase binders from crude extract of Corydalis yanhusuo.
METHODS AND RESULTS:
This approach was based on the retention of binders by acetylcholinesterase immobilized zeolite. The retained acetylcholinesterase binders were eluted and analyzed by ultra-high performance liquid chromatography and quadrupole-time-of-flight mass spectrometry. The powder X-ray diffraction (XRD), transmission electron microscopy (TEM), and Fourier transform infrared (FT-IR) spectroscopy techniques were employed for the characterization of acetylcholinesterase immobilized zeolite. Some experimental conditions such as incubation temperature, time, buffer pH and ion strength, which may affect binding capability, were investigated by using coptisine as a model inhibitor. The optimal incubation conditions were as follows: wash times: 4, wash solvent: 50% methanol-water, incubation time: 20 min, temperature: 37 °C, ion strength: 10 mM, pH: 7.4. The proposed approach was successfully applied for the extraction of acetylcholinesterase binders from crude extract of Corydalis yanhusuo. These binders were further validated by acetylcholinesterase inhibitory assay.
CONCLUSIONS:
Fourteen acetylcholinesterase inhibitors were identified, and ten of which, including dehydrocorydaline, allocryptopine, corydaline, Dehydroglaucine, protopine, tetrahydrocoptisine, tetrahydropalmatine, corynoline, tetrahydrocolumbamne and tetrahydroberberine, were reported for the first time. In addition, the merits and shortcomings of zeolite based solid-phase extraction approach were compared with that of magnetic nanoparticles based solid-phase extraction approach.

Dehydroglaucine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Dehydroglaucine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Dehydroglaucine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8296 mL 14.1479 mL 28.2957 mL 56.5915 mL 70.7394 mL
5 mM 0.5659 mL 2.8296 mL 5.6591 mL 11.3183 mL 14.1479 mL
10 mM 0.283 mL 1.4148 mL 2.8296 mL 5.6591 mL 7.0739 mL
50 mM 0.0566 mL 0.283 mL 0.5659 mL 1.1318 mL 1.4148 mL
100 mM 0.0283 mL 0.1415 mL 0.283 mL 0.5659 mL 0.7074 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Dehydroglaucine

Antiplatelet aggregation constituents from Annona purpurea.[Pubmed:9868142]

J Nat Prod. 1998 Dec;61(12):1457-61.

Bioactivity-directed fractionation led to the isolation of 19 compounds, including three oxoaporphines, oxopurpureine (5), oxonuciferine (6), and oxoglaucine (7); three aporphines, (+)-predicentrine (8), (-)-glaucine (9), and thalbaicalidine (10); one aporphine sensu stricto, N-formyl-purpureine (11); one proaporphine, glaziovine; one phenanthrene, thalicpureine (12); two 6a,7-dehydroaporphines, dehydrolirinidine (13) and 7-hydroxy-Dehydroglaucine (14); four flavonoids, quercetin-3-O-rhamnoside, kaempferol-3-O-rhamnoside, isorhamnetin-3-O-rhamnoside, and tanarixetin-3-O-rhamnoside; one purine, adenine; one lactam amide, squamolone; and two steroids, beta-sitosterol and beta-sitosterol-beta-D-glucoside from the MeOH extract of the leaves of Formosan Annona purpurea. Among them, 11-14 were characterized as new compounds and alkaloids, 5-8, 10, and 12-14 exhibited significant antiplatelet aggregation activity.

Glaucine analogues as inhibitors of mouse splenocyte activity.[Pubmed:9812336]

Pharmazie. 1998 Oct;53(10):694-8.

The inhibitory effect of 15 semi-synthetic analogues of glaucine (1) on the lipopolysaccharide (LPS)-induced and the concanavalin A (Con A)-induced proliferation of mouse splenocytes was compared in vitro. Isoboldine (3), bracteoline (4) and Dehydroglaucine (9) showed a significantly higher potency to suppress LPS-induced proliferation than 1, while 7-hydroxy-4-methylglaucine (8), 7-formylDehydroglaucine (11), 7-acetylDehydroglaucine (13), 7-benzoylDehydroglaucine (14), oxoglaucine (15) and glaucine-quinol (16) were less inhibitory. Compounds 3, 4, boldine (5), 15 and 16 surpassed significantly the inhibition expressed by 1 on Con A-induced proliferative response. The effect was equal to the inhibition determined for mitomycin C (Mit C) with both mitogens. In contrast to all others analogues, thaliporphine (2) stimulated splenocyte proliferation in both assays. Antibody response against sheep red blood cells (SRBC) was lowered most strongly by cataline (6), 7-methylDehydroglaucine (10) and 16.

Comparative study of the hypotensive effect of a group of structural derivatives of glaucine.[Pubmed:1819921]

Acta Physiol Pharmacol Bulg. 1991;17(2-3):98-103.

A comparative study was made on the hypotensive effect of a group of dehydrogenated structural derivatives of the alkaloid glaucine. The compounds studied induced a slowly occurring marked decrease in the blood pressure. Applied intravenously, they did not manifest the initial brief and very pronounced phase of the hypotensive effect, typical of glaucine, and failed to change substantially the respiration and the cardiac activity of the experimental animals. The most marked hypotensive effect was demonstrated by 7-benzoyl-Dehydroglaucine (DG4), which reduced the blood pressure by about 50 and 60% respectively, when applied in doses of 1 mg/kg and 2.5 mg/kg. Applied duodenally, the dehydrogenated glaucine derivatives also manifested a gradually occurring hypotensive effect, whereby DG4 again caused the most pronounced blood pressure drop. Depending on the DG4 and glaucine doses used, the pressor effects of noradrenaline (NA) and nicotine (NIC) were moderately to strongly suppressed or completely inhibited. In experiments on cat membrana nictitans glaucine also suppressed moderately (2.5 mg/kg) or markedly (5 mg/kg) the contractile effects of NIC and NA, while DG4 did not influence (1 mg/kg) or potentiated (2.5 mg/kg) these effects.

Minor Alkaloids of Corydalis bulbosa, Structure of Bulbodione.[Pubmed:17340280]

Planta Med. 1984 Apr;50(2):136-8.

As a result of the reinvestigation of the alkaloid content of CORYDALIS BULBOSA (L.) DC. (Papaveraceae), growing in Bulgaria, a new 8,11-dioxoaporphine alkaloid, named bulbodione, together with dihydrosanguinarine, Dehydroglaucine, (+/-)-sinactine, glaucinone and bicucullinine were isolated. These six alkaloids had not been detected in our initial study of the plant. The structure of buldodione was elucidated on the basis of spectral data and confirmed by synthesis of the alkaloid by means of Fremy's radical oxidation of bulbocapnine. The identification of the known alkaloids was obtained from their IR and (1)H-NMR spectral data and by direct comparison with authentic samples.

Pharmacological studies of a group of semi-synthetic structural analogues of glaucine.[Pubmed:543409]

Acta Physiol Pharmacol Bulg. 1979;5(4):3-12.

Glaucine and the newly-synthesized compounds possess some general properties conditioned by the common apomorphine structure - inhibition of the central nervous system, brief decrease in blood pressure and spasmolytic action. At the same time the changes in the structure of glaucine lead to quantitative or qualitative changes in some of its effects. Substitution of hydrogen in 3rd position with -CH2. NH-group reduces glaucine toxicity 3.5 times. Still greater decrease in the toxicity (7.5-10 times) is found in the case of N-oxidation or dehydrogenation of glaucine. The extension of the methyl group in 3rd position with a hydroxy group or with an amide residue of the benzoic acid, as well as the dehydrogenation and N-oxidation of glaucine, lead to intensification of the inhibitory action on the central nervous system. With the exception of 7-methyl Dehydroglaucine which has antitussive action similar to glaucine, the other glaucine structural analogues do not possess this property. Both glaucine and its structural analogues exercise a bronchoconstrictor effect. 3-Aminomethyl derivatives preserve the spasmolytic activity of glaucine, and their several-fold lower toxicity makes them more promising spasmolytic agents than glaucine. Dehydrogenation and N-oxidation of glaucine reduce considerably its spasmolytic action.

Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L.[Pubmed:807704]

J Pharm Sci. 1975 May;64(5):789-92.

Alcoholic extracts of the heartwood of Liriodendron tulipifera have demonstrated antimicrobial activity against Staphylococcus aureus, Mycobacterium smegmatis, Candida albicans, and Aspergillus niger. The antimicrobial activity was associated only with the alkaloidal fraction. Separation of the active alkaloidal fraction by chromatography led to the isolation and identification of Dehydroglaucine and liriodenine as the active components. Several other alkaloidal derivatives were prepared and tested. In addition to the active alkaloids, michelabine was also identified in the tertiary nonphenolic base fraction along with the lignan, lirioresinol-B-dimethyl ether, and two N-acetylnoraporphine alkaloids from the nonbasic fraction.

Keywords:

Dehydroglaucine,22212-26-6,Natural Products, buy Dehydroglaucine , Dehydroglaucine supplier , purchase Dehydroglaucine , Dehydroglaucine cost , Dehydroglaucine manufacturer , order Dehydroglaucine , high purity Dehydroglaucine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: